Product image of Neupogen (Filgrastim) supplied by GNH India

Neupogen

Active Ingredient:
Filgrastim
Origin:
EU

Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as an injectable solution for subcutaneous use. It treats chemotherapy‑induced neutropenia, neutropenia associated with bone‑marrow transplantation, severe chronic neutropenia and agranulocytosis.

GNH India supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neupogen (filgrastim) is used to stimulate neutrophil production in patients with conditions that cause low white‑blood‑cell counts.

  • Chemotherapy‑induced neutropenia: shortens the duration of neutropenia and reduces infection risk.
  • Neutropenia associated with bone‑marrow transplantation: supports engraftment and accelerates neutrophil recovery.
  • Severe chronic neutropenia: raises neutrophil counts and lowers the frequency of infections.
  • Agranulocytosis: hastens restoration of normal neutrophil levels.

How It Works

  • Filgrastim is a recombinant form of human granulocyte colony‑stimulating factor. After subcutaneous injection it binds to the G‑CSF receptor on hematopoietic progenitor cells in the bone marrow, activating JAK/STAT, MAPK and PI3K pathways that drive proliferation, differentiation and activation of neutrophil precursors, resulting in increased circulating neutrophils.

Side Effects

Filgrastim may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Bone pain: aching discomfort, often in the limbs or back.
  • Injection site reactions: redness, swelling or mild tenderness.
  • Fever: low‑grade temperature elevation.
  • Headache: mild to moderate intensity.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Splenic rupture: sudden left‑upper‑quadrant pain, possible shock.
  • Acute respiratory distress syndrome: severe breathing difficulty.
  • Anaphylaxis: rapid onset of hives, swelling, airway compromise.
  • Leukocytosis: excessively high white‑blood‑cell count.

Precautions & Warnings

Before initiating filgrastim therapy, clinicians should consider several safety measures.

  • Monitor blood counts: perform regular CBCs to track neutrophil response.
  • Assess splenic size: watch for left‑upper‑quadrant pain that may signal splenomegaly.
  • Avoid in patients with hypersensitivity: discontinue if severe allergic reaction occurs.
  • Use caution in sickle‑cell disease: filgrastim may precipitate vaso‑occlusive crises.
  • Pregnancy and lactation: safety not established; weigh benefits against potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Filgrastim can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Concurrent myelosuppressive chemotherapy: may mask true neutrophil recovery.
  • Cytarabine: additive myelosuppressive effect.
  • High‑dose corticosteroids: may diminish filgrastim activity.

Moderate Interactions (Monitor Closely)

  • Antibiotics (e.g., quinolones): may alter infection risk assessment.
  • Live attenuated vaccines: immune response may be blunted.
  • ACE inhibitors: possible increased risk of hypotension with rapid neutrophil rise.

Frequently Asked Questions

Neupogen (filgrastim) is prescribed to increase neutrophil counts in patients who have low white‑blood‑cell levels due to chemotherapy, bone‑marrow transplantation, severe chronic neutropenia, or agranulocytosis. By boosting neutrophils, it helps reduce the risk of infections in these vulnerable groups.

Filgrastim is a recombinant form of human granulocyte colony‑stimulating factor. It binds to the G‑CSF receptor on bone‑marrow progenitor cells, activating intracellular signaling that drives the proliferation, differentiation and activation of neutrophil precursors, leading to higher circulating neutrophil numbers.

The dose of Neupogen is individualized by the prescribing clinician based on the patient’s weight, indication and laboratory values. Healthcare professionals calculate the appropriate amount and frequency, and patients should follow the prescriber’s specific instructions.

Safety data for filgrastim in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neupogen (filgrastim) is a short‑acting recombinant G‑CSF, similar in efficacy to other filgrastim‑based products. Longer‑acting agents such as pegfilgrastim require fewer injections but have different pharmacokinetics. Choice of product depends on clinical setting, dosing convenience and cost considerations.

Neupogen must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Neupogen is supplied as an injectable solution for subcutaneous injection. A healthcare professional prepares the dose using a sterile syringe and administers it into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique.

Serious risks include splenic rupture, acute respiratory distress syndrome, severe allergic reactions (anaphylaxis) and uncontrolled leukocytosis. Patients should be monitored for sudden abdominal pain, respiratory difficulty, signs of hypersensitivity, and unusually high white‑blood‑cell counts.

Neupogen is contraindicated in individuals with known hypersensitivity to filgrastim or any of its excipients. Caution is advised for patients with a history of splenic disorders, sickle‑cell disease, or those receiving concurrent myelosuppressive therapies unless specifically directed by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Filgrastim

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT